289. Cronkhite-Canada syndrome Clinical trials / Disease details
Clinical trial : 1 / Drug : 1 - (DrugBank : 1) / Drug target gene : 0 - Drug target pathway : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000025246 | 2016/12/13 | 13/12/2016 | Safety and efficacy of indigo naturalis for chronic enteropathy associated with SLCO2A1 and Cronkhite-Canada syndrome. | Safety and efficacy of indigo naturalis for chronic enteropathy associated with SLCO2A1 and Cronkhite-Canada syndrome. - Safety and efficacy of indigo naturalis for chronic enteropathy associated with SLCO2A1 and Cronkhite-Canada syndrome. | chronic enteropathy associated with SLCO2A1 and Cronkhite-Canada syndrome | indigo naturalis 2g/day for oral administration is be administered daily in 2 divided doses during 8weeks. | Keio University Gastroenterology and Hepatology | NULL | Complete: follow-up complete | 20years-old | 69years-old | Male and Female | 6 | Not selected | Japan |